China Biopharmaceuticals (01177): LM-24C5 "CEACAM5/4-1BB Bispecific Antibody" Phase II Clinical Trial Application Approved by NMPA

Financial news from Smart Finance App: China Biopharmaceuticals (01177) announced that its wholly-owned subsidiary, Lixin Medical Technology (Shanghai) Co., Ltd. (Lixin Medical), has received approval from the National Medical Products Administration (NMPA) of China for clinical trials of its innovative drug LM-24C5 "CEACAM5/4-1BB bispecific antibody." The approval allows Lixin Medical to conduct a Phase II clinical trial in combination with other anti-tumor drugs in patients with advanced solid tumors that are CEACAM5 positive.